Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities: 2022

Historic Preferred Stock Liabilities for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2022 value amounting to $185.0 million.

  • Lexeo Therapeutics' Preferred Stock Liabilities changed negligibly% to $185.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $185.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $185.0 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Lexeo Therapeutics reported Preferred Stock Liabilities of $185.0 million as of FY2022.
  • Lexeo Therapeutics' 5-year Preferred Stock Liabilities high stood at $185.0 million for FY2022, and its period low was $185.0 million during FY2022.
  • In the last 1 years, Lexeo Therapeutics' Preferred Stock Liabilities had a median value of $185.0 million in 2022 and averaged $185.0 million.